Suzhou Industrial Park Heshun Electric
300141
Guangdong Xiongsu Technology Group
300599
Sichuan Chuanhuan Technology
300547
Shanghai Wisdom Information Technology
301315
KANGNONG SEED
837403
CN Stock MarketDetailed Quotes
688302 Hinova Pharmaceuticals Inc.
- 30.22
- +0.23+0.77%
Market Closed Dec 27 15:00 CST
2.99BMarket Cap-14.23P/E (TTM)
30.85High29.81Low8.60KlotVolume30.04Open29.99Pre Close26.13MTurnover1.18%Turnover RatioLossP/E (Static)99.02MShares53.2852wk High2.43P/B2.20BFloat Cap22.6052wk Low35.99Limit Up72.72MShs Float78.77Historical High23.99Limit Down3.47%Amplitude22.60Historical Low--Dividend TTM30.39Avg Price3.64KlotAsk--Div YieldTTM100Lot Size4.35KlotBid
Hinova Pharmaceuticals Inc. News
Express News | Summary of shareholding reductions of listed companies on December 4.
Third Quarter Report 2024
Hailan Pharmaceutical (688302.SH) released its performance for the first three quarters, with a net loss of 0.154 billion yuan.
Hochuen Pharmaceuticals (688302.SH) disclosed the third quarter report for 2024, achieving revenue of 11...
Haisco Pharmaceutical Co., Ltd. (688302.SH): The oral PROTAC drug HP568 tablets for the clinical trial of ER+/HER2- advanced breast cancer obtained the Drug Clinical Trial Approval Letter.
Gelonghui October 15th | Haichuang Pharmaceutical (688302.SH) announced that it has received the "Drug Clinical Trial Approval Notice" issued by the China National Medical Products Administration Drug Evaluation Center, approving the HP568 tablets for clinical trials for the treatment of late-stage breast cancer with estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2- late-stage breast cancer). According to the announcement, as of this announcement date.
Haisco Pharmaceutical (688302.SH): Yingchuang Power has cumulatively reduced its shareholding by 1%.
GeLongHui, October 14th | HaiChuang Pharmaceutical (688302.SH) announced that the company recently received a notice from YingChuang Power regarding the expiration of the shareholding reduction plan period and the results of the reduction. As of October 14, 2024, the current shareholding reduction plan period has expired. During the implementation of this shareholding reduction plan, YingChuang Power has cumulatively reduced 990,150 shares of the company's stock, accounting for 1.00% of the total share capital of the company.
Express News | Star market closing: SSE Science and Technology Innovation Board 50 Index fell by 0.48%, medical instruments and biopharmaceutical sectors declined.
Express News | Star Market Closing Report: Shares of innovative drug concept stocks in Haichuang Pharmaceutical hit the limit up, while the software sector collectively rose.
Hinova Pharmaceuticals Gets US FDA Approval for Fatty Liver Disease Clinical Trials
Haisco Pharmaceutical (688302): The commercialization of Daunzaruram is imminent, and the clinical progress of PROTAC is promising.
Investment Highlights 2024 First Half Performance: No pharmaceutical sales revenue in the first half of 2024, sales expenses of 5.769 million yuan, a year-on-year increase of 280%; management expenses of 21.367 million yuan, a year-on-year decrease of 46%; research and development expenses 8
Haisco Pharmaceutical (688302.SH): HP515 tablets approved for clinical trials to treat non-alcoholic fatty liver disease.
Hai Chuang Pharmaceutical (688302.SH) announced that recently, the company has received the pharmaceutical evaluation report issued by the China National Medical Products Administration...
Express News | Haitian Pharmaceutical: Clinical trial for HP515 tablets approved.
Hai Chuang Pharmaceutical (688302): Continuous progress in research and development.
Event: Recently, the company released the 2024 interim report. In the first half of 2024, the company did not obtain commercial sales approval for any pharmaceuticals, achieving revenue of 0.1097 million yuan; net income attributable to the parent company was a loss of 0.1 billion yuan, compared to a loss of 1.6 billion yuan in the same period last year.
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Haisun Pharmaceutical (688302.SH): net loss of 0.1 billion yuan in the first half of the year.
On August 23, Hai Chuang Pharmaceuticals (688302.SH) announced its semi-annual report for 2024. The operating income for the reporting period was 0.1097 million yuan; the net income attributable to shareholders of the listed company was -0.1 billion yuan, with a narrower year-on-year loss; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.11 billion yuan; the basic earnings per share was -1.01 yuan.
Express News | Star market closing review: Star 50 index fluctuated and closed up 0.03%. The medical instruments sector continued to decline.
Express News | Star Market closing review: Aviation and aerospace stocks performed well, semiconductors sector fluctuated.
Express News | Star review: The first day of Nlongtu's listing rose more than 88%, and the photovoltaic sector rose collectively.
Express News | Hai-Chuang Pharmaceuticals: Clinical trials of HP560 tablets for treating myelofibrosis have been approved.
Express News | Star Market Closing Review: Photovoltaic Sector Leads the Rise, Most of the Semiconductor Sector is Down.
